Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz ▼ (ixekizumab): Användning hos patienter som genomgår kirurgiska ingrepp

Säkerhet och effektivitet av ixekizumab hos patienter som genomgår kirurgiska ingrepp är inte fastställd eftersom inga formella studier har utförts.

SE_cFAQ_IXE395_USE_IN_PATIENTS_UNDERGOING_SURGICAL_PROCEDURES_PsO_PsA_axSpA
SE_cFAQ_IXE395_USE_IN_PATIENTS_UNDERGOING_SURGICAL_PROCEDURES_PsO_PsA_axSpA
en-US

General Recommendations for Biologic Therapies

The information provided is for reference only and does not constitute a treatment recommendation. Health care decisions to prescribe ixekizumab should be based on the best clinical judgment of the prescribing healthcare practitioner.

In general, psoriasis treatment guidelines from the British Association of Dermatologists recommend stopping biologic therapy for at least four half-lives prior to major elective surgical procedures, and restarting biologic treatments postoperatively, provided that wound healing is satisfactory and there is no evidence of infection.1,2

In general, the American College of Rheumatology and American Association of Hip and Knee Surgeons recommend stopping biologic medications prior to surgery and scheduling surgery at the end of the dosing cycle. It is also recommended to resume medications at minimum 14 days after surgery in the absence of wound healing problems, surgical site infection, or systemic infection.3

Ixekizumab Label Information

The mean elimination half-life is 13 days in patients with plaque psoriasis, psoriatic arthritis, radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis.4

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.4

Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.4

References

1Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019. http://dx.doi.org/10.1111/j.1365-2133.2009.09505.x

2Bakkour W, Purssell H, Chinoy H, et al. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J Eur Acad Dermatol Venereol. 2016;30(1):86-91. http://dx.doi.org/10.1111/jdv.12997

3Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res (Hoboken). 2017;69(8):1111-1124. http://dx.doi.org/10.1002/acr.23274

4Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Glossary

axSpA = axial spondyloarthritis

PsA = psoriatic arthritis

Datum fӧr senaste ӧversyn 2020 M03 03


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss